Rebeca M. Lozano
Salamanca, CL, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Clinical features and management for CDK4/6 inhibitor-DILI.
Journal: JHEP reports : innovation in hepatology
Published: January 29, 2026
Clinical features and management for CDK4/6 inhibitor-DILI.
Journal: JHEP reports : innovation in hepatology
Published: January 29, 2026
PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer.
Journal: Cancer medicine
Published: May 28, 2024
Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 04, 2023
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
Journal: European urology oncology
Published: July 15, 2023
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma.
Journal: Cancers
Published: January 03, 2023
Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 07, 2022
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.
Journal: The Prostate
Published: September 16, 2022
Implications of DNA damage repair alterations for the management of prostate cancer.
Journal: Current opinion in urology
Published: March 10, 2022
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
Journal: The Prostate
Published: June 24, 2021
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.
Journal: Cancers
Published: March 12, 2021
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study.
Journal: Frontiers in oncology
Published: February 24, 2021
Last Updated: 09/26/2026